Disease: Solid Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE The tumor site-agnostic clinical development of TRK inhibitors for pediatric solid tumors is a current example of how the combination of genetic testing and innovative clinical trial design can accelerate the clinical development of targeted agents for pediatric patients. 31749132 2020
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE The FDA has approved entrectinib for patients with any solid tumor bearing <i>NTRK</i> fusions, making it the second TRK inhibitor to receive a tissue-agnostic approval; larotrectinib was the first. 31471291 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Preliminary findings from a phase I study of LOXO-195 show that the investigational agent appears effective in patients with <i>NTRK</i> fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. 30936083 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Larotrectinib for the treatment of TRK fusion solid tumors. 30350734 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profound therapeutic responses, resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors, regardless of histology. 29920189 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Some clinical trials are currently evaluating the efficacy of Trk protein-target drugs in different types of solid tumors. 28650560 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Tropomyosin-related kinase A (TRKA) translocations have oncogenic potential and have been found in rare cases of solid tumors. 30046390 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. 28578312 2017
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE To our knowledge, this is the first clinical evidence of efficacy for therapeutic inhibition of TRKA in a solid tumor, illuminating a genomic-driven strategy to identify CRCs reliant on this oncogene to be clinically targeted with entrectinib. 26563355 2016
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE The ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. 26181203 2015
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 Biomarker phenotype BEFREE Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. 15637590 2005
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE TrkA protein membrane expression was detected in carcinoma cells in 30 of 77 (39%) effusions and 64 of 78 (82%) solid tumors. 11705863 2001
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.100 AlteredExpression phenotype BEFREE Met protein is a tyrosine kinase receptor for hepatocyte growth factor (HGF). c-Met has morphogenic, mitogenic, and motogenic properties and is overexpressed in many solid tumors. 11369990 2001